The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
Health and Me on MSN4d
FDA Approves Qfitlia For Hemophilia PatientsThe approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...
The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
Zacks Investment Research on MSN6d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United StatesSanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback